These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25880749)

  • 21. Designing of inhibitors against drug tolerant Mycobacterium tuberculosis (H37Rv).
    Singla D; Tewari R; Kumar A; Raghava GP;
    Chem Cent J; 2013 Mar; 7(1):49. PubMed ID: 23497593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does rational selection of training and test sets improve the outcome of QSAR modeling?
    Martin TM; Harten P; Young DM; Muratov EN; Golbraikh A; Zhu H; Tropsha A
    J Chem Inf Model; 2012 Oct; 52(10):2570-8. PubMed ID: 23030316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae.
    González-Díaz H; Prado-Prado F; García-Mera X; Alonso N; Abeijón P; Caamaño O; Yáñez M; Munteanu CR; Pazos A; Dea-Ayuela MA; Gómez-Muñoz MT; Garijo MM; Sansano J; Ubeira FM
    J Proteome Res; 2011 Apr; 10(4):1698-718. PubMed ID: 21184613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
    J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR.
    Chen G; Luo X; Zhu W; Luo C; Liu H; Puah CM; Chen K; Jiang H
    Bioorg Med Chem; 2004 May; 12(9):2409-17. PubMed ID: 15080937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
    Li SN; Li HQ
    Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors.
    Mao Y; Zhu W; Kong X; Wang Z; Xie H; Ding J; Terrett NK; Shen J; Shen J
    Bioorg Med Chem; 2013 Jun; 21(11):3090-104. PubMed ID: 23602524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
    Beckers T; Sellmer A; Eichhorn E; Pongratz H; Schächtele C; Totzke F; Kelter G; Krumbach R; Fiebig HH; Böhmer FD; Mahboobi S
    Bioorg Med Chem; 2012 Jan; 20(1):125-36. PubMed ID: 22169601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
    Shih KC; Lin CY; Zhou J; Chi HC; Chen TS; Wang CC; Tseng HW; Tang CY
    J Chem Inf Model; 2011 Feb; 51(2):398-407. PubMed ID: 21182293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
    Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
    Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
    Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational design and chemometric QSAR modeling of Plasmodium falciparum carbonic anhydrase inhibitors.
    Singh S
    Bioorg Med Chem Lett; 2015 Jan; 25(1):133-41. PubMed ID: 25466203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A web server for predicting inhibitors against bacterial target GlmU protein.
    Singla D; Anurag M; Dash D; Raghava GP
    BMC Pharmacol; 2011 Jul; 11():5. PubMed ID: 21733180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
    Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
    Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
    Engel J; Richters A; Getlik M; Tomassi S; Keul M; Termathe M; Lategahn J; Becker C; Mayer-Wrangowski S; Grütter C; Uhlenbrock N; Krüll J; Schaumann N; Eppmann S; Kibies P; Hoffgaard F; Heil J; Menninger S; Ortiz-Cuaran S; Heuckmann JM; Tinnefeld V; Zahedi RP; Sos ML; Schultz-Fademrecht C; Thomas RK; Kast SM; Rauh D
    J Med Chem; 2015 Sep; 58(17):6844-63. PubMed ID: 26275028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
    Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KiDoQ: using docking based energy scores to develop ligand based model for predicting antibacterials.
    Garg A; Tewari R; Raghava GP
    BMC Bioinformatics; 2010 Mar; 11():125. PubMed ID: 20222969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S; Madala KK; Jamil K
    J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinase inhibitor recognition by use of a multivariable QSAR model.
    Sprous DG; Zhang J; Zhang L; Wang Z; Tepper MA
    J Mol Graph Model; 2006 Jan; 24(4):278-95. PubMed ID: 16253531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.